Breast-Conserving Surgery Market Report Scope & Overview:
The breast-conserving surgery market size was valued at USD 2.36 billion in 2024 and is expected to reach USD 4.18 billion by 2032, growing at a CAGR of 7.47% over the forecast period of 2025-2032.
The global breast-conserving surgery market is expected to grow at a steady rate due to the increasing awareness of breast cancer screening and early diagnosis. The trend toward less invasive surgery with favorable cosmetic results is motivating patients to select lumpectomy and segmental mastectomy rather than complete mastectomy. Emerging technologies that improve tumor localization, intraoperative imaging, and margin assessment are broadening the scope of precision surgery. Meanwhile, an increasing number of healthcare policies, insurance coverage, and oncological guidelines supporting the use of breast-conserving procedures further facilitate the adoption of breast-conserving procedures globally.
The U.S. breast-conserving surgery market size was valued at USD 0.69 billion in 2024 and is expected to reach USD 1.19 billion by 2032, growing at a CAGR of 7.14% over the forecast period of 2025-2032.
North America breast-conserving surgery dominated the market, contributing to the growth in the U.S. due to higher healthcare expenditure, widespread uptake of breast cancer screening programs that are effective at the early stages of breast cancer, and wide availability and accessibility of minimally invasive surgical technology. The country is further bolstered in its lead in the region by strong adoption of intraoperative imaging and tumor localization devices, coupled with a favorable reimbursement framework.
Through pooled data from nearly 1.2 million mammograms between Germany and the U.S., a combination of artificial intelligence (AI) and radiologist review increased breast cancer detection rates by 2.6% over radiologist review alone. Their findings were reported in July 2022 in The Lancet Digital Health.
Market Dynamics:
Drivers:
- Rising Prevalence of Breast Cancer is Driving the Market Growth
The key factor responsible for fueling the breast-conserving surgery market trends is the rising incidence of breast cancer in the elderly population, especially above the age of 40 years globally. The increasing awareness about breast cancer and improved screening facilities have led to an upsurge in early-stage diagnosis (Stage 0–II). These early detections allow patients to qualify for breast-saving procedures, such as lumpectomy, which seeks to excise the tumor while retaining most, if not all, of the breast. If breast cancer continues to grow in incidence globally, then the need for effective and less disfiguring surgical solutions would also grow.
The NIH estimates that by 2040, breast cancer incidence will be well over 3 million new cases, up from 2.3 million in 2020 globally, indicating an ever-increasing need for early detection and breast-conserving surgical (BCS) procedures.
Since, in early-stage breast cancer, almost two-thirds of patients now opt for lumpectomy, and nearly six in ten hospitals in the developed countries are using image-guided lumpectomy nowadays.
- Advancements in Surgical Technologies are Propelling the Market Growth
Breast-conserving surgeries have been revolutionized, as technological innovations are improving the precision of breast surgeries and how safe it is to treat cancers while leaving the breast intact. For instance, wireless tumor localization systems (SCOUT and Magseed), intraoperative imaging, and real-time margin assessment devices enable surgeons to precisely locate and remove tumors while sparing healthy tissue. These tools help mitigate the chance of repeated surgeries and enhance patient outcomes. Continued advancement of image-guided surgery, coupled with energy-based dissection instruments, further increases confidence in the BCS technique, allowing for wide uptake of BCS in the hospital and ambulatory settings.
Moreover, another publication in Nature (2020) found that analyzing over 91,000 mammograms from the U.S. and the U.K. demonstrated that the use of AI was associated with significantly lower false-positive rates, nearly a 6% lower in the U.S. and 1.2% lower in the U.K., which also supports its role in improving early diagnosis.
Restraints:
- High Cost of Breast-Conserving Procedures and Equipment is Challenging the Growth of the Market
The cost factor is one of the key restraints in the breast-conserving surgery market growth, which further refers to the combined cost of advanced surgical procedures and technologies. Advancements, including wireless tumor localization, intraoperative imaging, margin assessment tools, and oncoplastic surgery, require costly instruments and distinct skills, which divert revenue and increase costs associated with the primary procedure. In most areas, especially in developing countries, these expenses are not captured by public or private insurance systems, leading to out-of-pocket costs for patients. Moreover, the upkeep and utilization of these high-tech devices increase the institutional cost, making it less appealing for smaller clinics and a few hospitals to adopt them. The high costs of hardware thus restrict the people who can most benefit from BCS from accessing it at scale.
Segmentation Analysis:
By Procedure
In 2024, the lumpectomy segment dominated the breast-conserving surgery market, holding the largest share with 42.16% due to lumpectomy being the most common procedure performed for early breast cancer treatment. A partial mastectomy, or lumpectomy, is a procedure in which only the tumor and a narrow margin of surrounding tissue are removed, leaving most of the affected breast in place. It provides clinical results comparable to mastectomy but with less physical and emotional trauma, hence it has become the preferred treatment among many patients and physicians. Moreover, high-end localization and imaging tools have increased the surgical precision and outcome, thereby strengthening their position.
The quadrantectomy segment is anticipated to exhibit the fastest CAGR throughout the forecast period, owing to a higher availability of high-risk patients with a higher demand for extensive tumor resection. Quadrantectomy is the surgical excision of larger parts of breast tissue, and in some cases, it may also help reduce the chances of the cancer recurring. The increase in local market adoption of this procedure is driven by improving surgical methods, resources, enhanced intraoperative imaging precision, and increasing use in the setting of multifocal or other more aggressive tumor characteristics. With changing patient education and commitment from oncologists, quadrantectomy is coming into prominence as an aggressive option for breast conservation.
By Product
The breast-conserving surgery market share in 2024 was led by the surgical excision devices segment with 43.16%, as these devices are used primarily to excise the cancerous tissue whilst ensuring minimal damage to the surrounding normal tissue. Such devices, from sophisticated scalpels and electrosurgical and radiofrequency instruments, are used in both standard-of-care lumpectomies and breast-conserving operations. They are invaluable due to their ability to achieve clean surgical margins and their functional role in reducing recurrence risk. They have consolidated a leading market position due to they are broadly available in most hospitals and surgical centers, and there is a steady clinical requirement for such devices.
The tumor localization devices segment is expected to register the highest growth during the forecast period, owing to a high focus on specific pre-surgical planning and accuracy. These include tools, such as magnetic seeds, radar reflectors, and radiofrequency identification (RFID) that enable surgeons to find the location of difficult-to-palpate tumors before surgical removal. With earlier diagnosis of breast cancer through screening, localization tools have become essential to excise the tumor completely while maximizing preservation of healthy tissue. Recent technological advancements, better patient comfort, and replacing wire localization with a wireless method are some of the factors leading to widespread adoption across health care systems.
By End-Use
The hospitals segment held the largest share of the breast-conserving surgery market in 2024, with a 78.05%, owing to their comprehensive surgical infrastructure, availability of multidisciplinary oncology teams, and access to advanced imaging and excision technologies. With a focus on post-operative care, diagnosis, and treatment, hospitals remain the leading institutions for performing these complex and early-stage breast cancer surgery types, such as quadrantectomy and lumpectomy. Furthermore, their expertise in complication management, intraoperative margin evaluation, and integrated radiotherapy and chemotherapy assistance can further substantiate the leadership of breast-conserving surgery by these centers.
The ambulatory surgery centers (ASCs) segment is anticipated to be the fastest growing segment during the forecast period, as the demand for economical and rapid recovery, and minimally invasive surgical solutions will likely rise during the forecast years. Ambulatory surgical center (ASC) placements yield high efficiency with minimal postoperative hospital stays in addition to decreased healthcare costs, and have gained acceptance for management of early-stage breast cancer. New technology for surgical instruments and imaging has allowed many complex procedures, such as breast-conserving surgeries, to be performed safely as outpatient procedures.
Regional Analysis:
North America dominated the breast-conserving surgery market with a 38.2% market share in 2024, owing to the advantages of a well-established health care infrastructure, high awareness regarding breast cancer screening, and early detection initiatives. The routine availability of novel diagnostic and surgical technologies, including intraoperative imaging and tumor localization systems, increases the accuracy and safety of breast-saving operations. Coupled with robust insurance coverage and favorable reimbursement policies in the U.S. and Canada, it has made the procedure more widely available. Moreover, the high investment in breast cancer research and the presence of key medical device players also support the dominance in the North American market.
Increasing incidence of breast cancer, increasing healthcare expenditure, coupled with rising accessibility to surgical care, are the factors that are expected to speed up the growth of the breast-conserving surgery market in the Asia Pacific region with an 8.12% CAGR over the forecast years. In response to improved awareness of early diagnosis by national screening programs, countries such as China, India, and Japan are increasingly employing breast-conserving techniques. The private healthcare infrastructure expansion, government-induced cancer control initiatives, and the rise of innovative surgical devices in the emerging countries also promote growth further. This is further accelerating regional adoption with increasing focus on patient quality of life and improved post-surgical outcomes.
The breast-conserving surgery market in Europe is witnessing significant growth attributed to the presence of developed healthcare systems, region-wide breast cancer screening programs, and a steady rise in females preferring minimally invasive treatment. Breast-conserving surgery is being driven in countries such as Germany, France, and the U.K. due to the introduction of new technologies in advanced imaging, tumor localization, and margin assessment for better surgical procedures.
Furthermore, increased focus on cosmetic results and quality of life in the post-operative scenario encourages the use of oncoplastic methods. The increasing support for the improvement of breast-conserving surgery across the European region is facilitated through the rise in R&D investment, along with favorable clinical guidelines, alongside government-supported cancer care initiatives.
The breast-conserving surgery market analysis in Latin America and the Middle East & Africa (MEA) is growing substantially, owing to increasing awareness about breast cancer and boosting accessibility to healthcare services. The countries' oncology infrastructure and screening programs are gradually developing, thus offering a higher chance to get breast cancer diagnosed at an early stage, which is a crucial opportunity when performing breast-conserving procedures. Such regions are accompanied by growth limitations due to the challenges of outdated surgical technologies, urban–rural access inequalities, and the limited budget in public health systems. However, investments under healthcare modernization, along with the rising demand for minimally invasive surgical options, are anticipated to continue ensuring market growth opportunities over the foreseeable future.
Key Players:
The breast-conserving surgery market companies, Hologic, BD (Becton, Dickinson and Company), Danaher Corporation, Carl Zeiss Meditec AG, Merit Medical Systems, Argon Medical Devices, Endomagnetics Ltd., SOMATEX Medical, Ranfac Corporation, Stryker Corporation, and other players.
Recent Developments:
- November 2024 – Antibody-drug conjugates (ADCs) hold out the promise of a new therapy, but the key to success will depend on the identification of the appropriate patients. Danaher partner Dr. David Rimm of Yale School of Medicine discussed existing diagnostic issues and solutions that could advance ADC use for the treatment of breast cancer.
- February 2024 – Merit Medical Systems, Inc., a global healthcare technology leader, has announced that it has obtained U.S. FDA 510(k) clearance for its Scout MD Surgical Guidance System, which is intended to enhance accuracy in breast-conserving surgery.
- March 2025 – Becton, Dickinson and Company (BD), a global medical technology leader, announced that the first patient had been treated in its Investigational New Drug (IDE) clinical trial. The trial is designed to facilitate BD's pursuit of Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the GalaFLEX LITE Scaffold, which was created to prevent capsular contracture recurrence in breast revision procedures.
Breast-Conserving Surgery Market Report Scope:
Report Attributes Details Market Size in 2024 USD 2.36 Billion Market Size by 2032 USD 4.18 Billion CAGR CAGR of 7.47% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook Key Segments • By Procedure (Lumpectomy, Quadrantectomy, Segmental Mastectomy)
• By Product (Tumor Localization Devices, Surgical Excision Devices, Margin Assessment Devices, Intraoperative Imaging & Navigation Devices)
• By End Use (Hospitals, Ambulatory Surgery Centers, Oncology/Specialty Clinics, Others)Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Company Profiles Hologic, BD (Becton, Dickinson and Company), Danaher Corporation, Carl Zeiss Meditec AG, Merit Medical Systems, Argon Medical Devices, Endomagnetics Ltd., SOMATEX Medical, Ranfac Corporation, Stryker Corporation, and other players.
